Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
ProShares UltraShort Bloomberg Crude Oil ETF
SCO
5
ProShares Ultra Bloomberg Crude Oil ETF
UCO
US Stock MarketDetailed Quotes
Eli Lilly and Co (LLY)
- 1082.920
- +18.180+1.71%
Close May 27 16:00 ET
- 1081.330
- -1.590-0.15%
Pre 06:02 ET
1.02TMarket Cap38.47P/E (TTM)
1093.000High1069.900Low2.59MVolume1072.260Open1064.740Prev Close2.81BTurnover0.28%Turnover Ratio47.19P/E (Static)941.74MShares1130.11552wk High32.69P/B1.02TFloat Cap619.39852wk Low6.23Dividend TTM939.33MShs Float1130.115Historical High0.58%Div Yield TTM2.17%Range %5.224Historical Low1084.293Avg Price1Lot Size
LLY Stock Chart
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
LLY Orderflow
Unit: --
LLY Orderflow Trend
IntradayDayWeekMonth
No Data
Eli Lilly and Co (LLY) News
Unfazed by the 'MFN' pricing hammer, Eli Lilly and Co vows to advance global drug launches
Eli Lilly and Co stated that despite uncertainties arising from the Trump administration’s proposed Most-Favored-Nation (MFN) drug pricing scheme, the company will continue advancing its global drug launch plans.
Eli Lilly and Co. published new research: Early intervention with tirzepatide in type 2 diabetes yields greater benefits.
Gelonghui, May 28 | According to Jiemian, Eli Lilly and Co has published detailed results from its SURPASS-EARLY study, which focuses on the early stage of type 2 diabetes diagnosis. The study showed that over a two-year follow-up period, patients treated with tirzepatide achieved significantly greater improvements in blood glucose control compared to those receiving conventional intensive therapy. Sixty percent of patients in the tirzepatide group attained normoglycemia, versus 24% in the conventional intensive therapy group. Beyond glycemic control, tirzepatide also demonstrated superior efficacy in reducing body weight and waist circumference, along with improvements in multiple metabolic parameters including lipid profiles, beta-cell function, and insulin sensitivity.
Eli Lilly Stock (LLY) Gets a Price Target Boost as Weight-Loss Drug Sales Accelerate
Leerink Partners Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Thermo Fisher (TMO) and Eli Lilly & Co (LLY)
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,251
Market Insights
China Concept Stocks China Concept Stocks
Chinese Concept Stocks refer to companies with core operations and revenue from Mainland China, listed on U.S. exchanges. They serve as a key bridge for global investors to access China's growth and innovation. Chinese Concept Stocks refer to companies with core operations and revenue from Mainland China, listed on U.S. exchanges. They serve as a key bridge for global investors to access China's growth and innovation.
View More
Hot Topics Hot Topics
Middle East conflict spreads to the stock market! How should investors respond?
The plot took a sharp turn! At a White House cabinet meeting on May 27, Trump publicly expressed dissatisfaction with the negotiations, reje
Futubull Options Sir
May 26 18:03
Options Sir on Macro | Big Week Ahead! US-Iran Deal May Materialize + PCE Data Looms—How to Navigate Markets Next?
牛牛課堂
Mar 4 17:09
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.